Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. - Wikidata - awgldk - TriplyDB

Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.

Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.

http://www.wikidata.org/entity/Q38083093

about

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients Assessing the Immunogenicity of Biopharmaceuticals Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.Future directions in inflammatory bowel disease management.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach.

P2860

Q26748630-2AE46AE8-6E0A-4831-9051-D50EC953FE7F Q26751485-AEFCDA74-0D50-4627-B6C9-FFAB742C18BE Q28078423-5248FB94-31E8-465D-8A88-18F1ED023447 Q34486159-41AB07B8-027F-4B90-AA36-7FB78916B723 Q36214720-6F3DD962-7E6E-4BF9-B96D-64FCF1F32430 Q37220066-EA29786C-962D-420C-9EC3-28FAD86BCBA2 Q37258726-CA269CA5-443D-48D4-982B-571AF0F1536A Q38205305-D0682B08-9DCD-4B9F-B947-45296948D282 Q38365041-4D5C8AB9-F237-4CF9-B417-69C28579DE74 Q38592363-B31CAF65-2C61-4A53-AFFE-AFFED97868C9 Q38898145-BC02B8EA-FC0E-4B52-B61C-A2220E054244 Q40748041-37D61BE0-369B-469B-8DEC-2D4DFB62F029 Q47807650-1D30BFE3-46B6-4BFB-8123-A5D294EC5D8D Q50049641-E13A46CE-AD91-48F6-92AF-2EA23C71EBC8

P2860

Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.

http://www.wikidata.org/entity/Q38083093

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Assessing immunogenicity of bi ...... bioanalytical considerations.

@en

type

label

Assessing immunogenicity of bi ...... bioanalytical considerations.

@en

prefLabel

Assessing immunogenicity of bi ...... bioanalytical considerations.

@en

P1433

Q38083093-5FAB1185-851B-4FD9-98F9-F18B9F127CCA

P1476

Q38083093-B8A63C43-4EB1-4C36-980E-B8FA244EC1ED

P2093

Q38083093-C9DBDF16-092E-4BB5-A5E0-269931902817

P2860

Q38083093-03E707D6-6B9B-4BBC-A513-48C364E30219

Q38083093-0C6CA35F-2666-4726-9A89-857789C3B759

Q38083093-15F42A60-43D8-4F7C-BCE3-AB058CE00882

Q38083093-1C2FCE76-9278-4860-A6CA-AD8FAD0D2B98

Q38083093-207F43FA-C4AD-4D50-B486-49474FEDA193

Q38083093-293A9355-9AA2-4092-8463-4F2A8B3EA264

Q38083093-4160012F-36B2-4AFC-BE46-866697FE2C23

Q38083093-42A8E9E4-D6EC-4F50-9D47-275D51729FD6

Q38083093-4A6C0F4D-1A2C-4295-A84E-A624FE52FABD

Q38083093-4D251FB0-7058-4779-AE30-A97EB27CD1A2

P304

Q38083093-6228F210-8621-4F26-A180-DE4E254FB55F

P31

Q38083093-5A495340-BD81-441C-83A2-B21E3AC50F9F

P356

Q38083093-9E071327-88C1-4721-9627-73B65A029FE1

P433

Q38083093-B62D6742-81FF-4D89-A98A-4309D81B59FF

P478

Q38083093-F372A67C-3B34-4153-BC24-393AE0401824

P577

Q38083093-0B29CBCB-4516-4DB0-B415-8D5F782A9A8C

P698

Q38083093-AF5B44F3-1DC1-4CB5-9770-79E08623658F

P356

P1433

P1476

Assessing immunogenicity of bi ...... bioanalytical considerations.

@en

P2093

Paul Chamberlain

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Predictors of infusion reactions during infliximab treatment in patients with arthritis.

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.

Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.

P304

561-574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/BIO.13.6

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23425272

http://www.w3.org/2001/XMLSchema#string